ZYBT Stock Analysis: Buy, Sell, or Hold?
ZYBT - Zhengye Biotechnology Holding Limited Ordinary Shares
$1.53
0.05 (3.38%)
▲
5d:
+31.9%
30d:
+10.87%
90d:
+102.65%
WAIT
LOW Confidence
Analysis Updated: Oct 14, 2026 12:00 AM ET
Earnings: Jul 28, 2026
0d
Get Alerted When ZYBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ZYBT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ZYBT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ZYBT is currently trading at $1.53, which is considered extended relative to its 30-day fair value range of $1.21 to $1.56.
Technical Outlook: Technically, ZYBT is showing sideways momentum. Immediate support is located at $1.09, while resistance sits at $2.89. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: ZYBT scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZYBT is showing sideways momentum. Immediate support is located at $1.09, while resistance sits at $2.89. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: ZYBT scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.21 -
$1.56
Company Quality Score
38/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
17.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: Strong upward momentum (+3.4%)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.21 -
$1.56
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.09
Resistance Level
$2.89
Current Trend
Sideways
Technical data as of
Oct 14, 2026
Fundamental Context
Revenue Growth (YoY)
-40.9%
Earnings Growth (YoY)
-79.6%
Profit Margin
-60.0%
Share & Embed Analysis
Last updated: October 15, 2026 12:33 AM ET
Data refreshes hourly during market hours. Next update: 1:33 AM
Data refreshes hourly during market hours. Next update: 1:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYBT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 53 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 64 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 54 HOLD |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$42 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 57 HOLD |
